Abstract | BACKGROUND: METHODS: RESULTS: Baseline characteristics were comparable between the two groups. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE. CONCLUSIONS:
|
Authors | Jah Yeon Choi, Cheol Ung Choi, Byoung Geol Choi, Yoonjee Park, Dong Oh Kang, Won Young Jang, Woohyeun Kim, Jin Oh Na, Jin Won Kim, Eung Ju Kim, Seung-Woon Rha, Chang Gyu Park, Hong Seog Seo, Myung Ho Jeong, Sung-Chull Chae, In-Whan Seong, Chang-Hwan Yoon, Kwang Soo Cha, Seok Kyu Oh, KAMIR-NIH Investigators |
Journal | BMC pharmacology & toxicology
(BMC Pharmacol Toxicol)
Vol. 22
Issue 1
Pg. 11
(02 04 2021)
ISSN: 2050-6511 [Electronic] England |
PMID | 33541430
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
- Atorvastatin
|
Topics |
- Aged
- Asian People
- Atorvastatin
(therapeutic use)
- Cardiovascular Diseases
(drug therapy, epidemiology, prevention & control)
- Diabetes Mellitus
(epidemiology)
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Hypercholesterolemia
(drug therapy)
- Male
- Middle Aged
- Registries
- Republic of Korea
(epidemiology)
- Rosuvastatin Calcium
(therapeutic use)
- Secondary Prevention
- Treatment Outcome
|